New hope for bile duct cancer: two drug combos tested
NCT ID NCT03044587
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 21 times
Summary
This study tested two different chemotherapy combinations in 93 people with advanced bile duct cancer that could not be removed by surgery. One group received a new drug called Nal-IRI along with standard drugs 5-FU and leucovorin, while the other group received gemcitabine plus cisplatin. The goal was to see how long the cancer stayed under control. This was a phase 2 trial, meaning it looked for promising results to guide future larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universitätsklinikum Ulm
Ulm, 89081, Germany
Conditions
Explore the condition pages connected to this study.